Mirum Pharmaceuticals, Inc. (MIRM)
Stock Price:
$20.15 USD
0.27 (1.36%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
511.61M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-67.91M |
| Shares Out |
25.39M |
| EPS (ttm) |
-9.33 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$20.15 |
| Previous Close |
$19.88 |
| Change ($) |
0.27 |
| Change (%) |
1.36% |
| Day's Open |
20.28 |
| Day's Range |
20.03 - 21.29 |
| Day's Volume |
47,342 |
| 52-Week Range |
6.51 - 28.31 |
More Stats
| Market Cap |
511.61M |
| Enterprise Value |
355.69M |
| Earnings Date (est) |
Aug 26, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
25.39M |
| Float |
6.86M |
| EPS (basic) |
-7.12 |
| EPS (diluted) |
-9.33 |
| FCF / Share |
-2.25 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
543,958 |
| Short Ratio |
4.05 |
| Short % of Float |
4.59% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
3.41 |
| Revenue |
n/a |
| Operating Income |
-70.59M |
| Net Income |
-67.91M |
| Free Cash Flow |
-55.62M |
| Net Cash |
155.92M |
| Net Cash / Share |
6.14 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-34.44% |
| ROE |
-60.80% |
| ROIC |
-69.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
4 |
| Overweight |
2 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$35.17*
(74.54% upside)
Low
27.0
Current: 20.15
High
65.0
Target: 35.17
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 |
|---|
| Revenue | - |
| Operating Income | -54.74 |
| Net Income | -52.55 |
| Shares Outstanding | 11.49 |
| Earnings Per Share | -4.58 |
| Operating Cash Flow | -39.36 |
| Capital Expenditures | -0.28 |
| Free Cash Flow | -39.64 |
| Cash & Equivalents | 117 |
| Total Debt | 3.65 |
| Net Cash / Debt | 113 |
| Assets | 147 |
| Liabilities | 16.36 |
| Book Value | 130 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Mirum Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
41 |
| CEO |
Christopher Peetz |
Stock Information
| Ticker Symbol |
MIRM |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MIRM |
Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its lead product candidate is maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. The company is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was founded in 2018 and is headquartered in Foster City, California.